论文信息 - Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies - 字舞流文

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

B. Cheson | T. Kipps | M. Federico | A. Cuneo | G. Verhoef | R. Herbst | F. Offner | A. Forero-Torres | M. Fanale | C. Bello | T. Goswami | R. Ibrahim | S. Gregory | S. Assouline | M. Hamadani | A. Sonet | J. Tomás | N. Elgeioushi | J. P. Oteyza